



ISSN: 2231-3656

Print: 2231-3648

## International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR | Vol.14 | Issue 1 | Jan - Mar -2024

www.ijpir.com

DOI : <https://doi.org/10.61096/ijpir.v14.iss1.2024.73-80>

### Research

## Formulation And *In Vitro* Evaluation Of Mouth Dissolving Tablets Of Daclatasvir Hydrochloride

Syed Asadulla Bakhtiary<sup>1</sup>, Srikant Pallothu Chowdary<sup>2</sup>, Syam Prasad Borra<sup>3</sup>, Mohammed Ibrahim<sup>4</sup>

<sup>1</sup>Professor & HOD, Department of Pharmacology, Prathap Narender Reddy College of Pharmacy, Peddeshapur, Shamshad, Telangana-509325, India



<sup>2</sup> Professor, Department of Pharmaceutics, Prathap Narender Reddy College of Pharmacy, Peddeshapur, Shamshad, Telangana-50932, India

<sup>3</sup> Assistant General Manager, Hetero Labs Limited, Gandhinagar, Hyderabad, Telangana- 500037, India

<sup>4</sup>Professor & Principal, Department of Pharmaceutical Chemistry & Analysis, Prathap Narender Reddy College of Pharmacy, Peddeshapur, Shamshad, Telangana-50932, India

\*Author for Correspondence: Syed Asadulla Bakhtiary

Email: dr.asadpnrcp@gmail.com

	<p><b>Abstract</b></p>
<p>Published on: 15 Nov 2023</p>	<p>The mouth dissolving tablets has various advantages which has a triat of is a super distintegrant made from potato starch by carboxymethylation and crosslinking for tablets and other oral solid disintegrants called Explotab. The Daclatasvir Dihydrochloride mouth dissolving capsules have been organized the use of the fast compression technique. There had been a complete of evaluation used to consider the tablets, inclusive of the factor of rest, hardness, thickness, tapped density, carr's index, hausner's ratio, weight variation, hardness, friability and the drug release. The half-life of the third-generation (F3) Daclatasvir Dihydrochloride drug in vitro was once estimated to be happening 19 seconds. The drug release pattern had been released under 30minutes. Studies the using of Fourier transmission infrared spectroscopy (FTIR) indicates that there are possible interactions between the drug and any of the formulated ingredients. The maximum water absorption ratio was shown by formulation F3 showed 98%. Water absorption ratio is propo1tional to dissolution rate profile as higher the water absorption ratio Higher the dissolution.</p>
<p>Published by: DrSriram Publications</p>	<p><b>Keywords:</b> Solutab, Explotab, orally disintegrating tablets &amp; Fourier radically change infrared spectroscopy studies.</p>
<p>2023  All rights reserved.</p>  <p><a href="#">Creative Commons Attribution 4.0 International License.</a></p>	

### INTRODUCTION

The oral route is the most popularly popular technique of affiliation due to its obvious ease of use, conservatism, and necessary societal significance. The most apparent disadvantage of the normally used oral estimates structures, such as drugs and holders, is situation in gulping, main to tolerant contradiction, specifically in pediatric and geriatric patients<sup>1</sup>. Patients who are ill and bedridden are now not the solely ones who can gain

from this; energetic sufferers who are working or visiting are additionally affected, specifically these who do not drinkwater.<sup>2</sup> The improvement of higher orally disintegrating pills (ODTs) has attracted a lot of interest in latest years. Many people, particularly these who have bother gulping, admire pills that dissolve in the mouth as an alternative than in the stomach. This case of dysphagia is portrayed. Difficulty swallowing (or dysphagia) is frequent during all age groups, however is greater familiar in these who are younger, older, much less mobile, have negative coordination, intellectual fitness issues, or have issues with regurgitation or growth<sup>(1-5)</sup>. The availability of harsh prescriptions throughout a number agencies is extended via ODTs with super flavor and taste.

The advantages of each dry and liquid counting are mixed in this technique of calculation. Ingenious ODT improvements take more than one medicines into account, have a exceptional flavor, and do not depart a terrible style or residue administration. Bioavailability problems with prescribed drugs that are hard to dissolve in water have caused lookup into whether or not or now not ODT can enhance the dissolution profile of prescription and medicine for hepatic processing.

Tablets that dissolve in the mouth are regarded through arrange of names, which includes or odispersible, speedy separating, mouth dissolving, rapid disintegrating, quickly dissolving, permeable, and rapimelts. Despite this, the unique phrases above are viewed ODTs by means of the US pharmacopoeia (USP)<sup>6,7</sup>. Recently, the US Food and Prescription Association (FDA) defined ODT as "As table estimations shape containing useful tongue." Breakdown recollections vary from a few seconds to a couple of minutes for most ODTs.

## MATERIALS AND METHODS

The materials used in this current research work are procured from reliable sources of Daclatasvir dihydrochloride, Bristol Myers Squibb, Polyplasdone XL, solutab, explotab, aspartame, talc, magnesium stearate and MCC are obtained from Oxford Laboratories Pvt Ltd., Mumbai, INDIA. All other reagents and chemicals used in this research work has been purchased from the reliable sources.

### Construction of standard graph

100 mg of Daclatasvir Dihydrochloride was dissolved in 100 mL of pH 6.8 phosphate buffer to give a concentration in 1 mg/mL (1000 Lg/mL) 1 ml was taken and diluted to 100 ml with pH6.8 phosphate buffer to give a concentration of 0.01 mg/ml (10 Lg/ml). From this stock solution aliquots of 0.5 ml, 1 mL 1.5 ml, 2 ml, 2.5 ml, were pipette out in 10 ml volumetric flask and volume was made up to the mark with pH 6.8 phosphate buffer to produce concentration of 5, 10, 15, 20 and 25µg/ml respectively. The absorbance of each concentration was measured at respective Amax is 294.

### Formulation development

Drug and different concentrations of super disintegrants (Polyplasdone XL, Solutab, Explo tab) and required ingredients were accurately weighed and passed through a40-meshscreentoget uniform size palticles and mixed in a glass motor for 15 min<sup>(8-15)</sup>.

**Table 1: Formulation table showing various compositions**

Ingredients	Formulations								
	F1	F2	F3	F4	FS	F6	F7	F8	F9
<b>Daclatasvir Dihydrochloride</b>	60	60	60	60	60	60	60	60	60
<b>PolyplasdoneXL</b>	15	30	45	-	-	-	-	-	-
<b>Solutab</b>	-	-	-	15	30	45	-	-	-
<b>Explotab</b>	-	-	-	-	-	-	15	30	45
<b>Aspaitame</b>	10	10	10	10	10	10	10	10	10
<b>Talc</b>	5	5	5	5	5	5	5	5	5
<b>Mgstreate</b>	4	4	4	4	4	4	4	4	4
<b>MCC</b>	56	41	26	56	41	26	56	41	26
<b>Total Weight</b>	150	150	150	150	150	150	150	150	150

### Thickness

The thickness of the tablets wasdetelmined by using Digital micrometer. 10 individual tablets from each batch were used and the results averaged.

### Weight variation

Twenty tablets were randomly selected from each batch and individually weighed. The average weight and standard deviation 3 batches were calculated. It passes the test for weight variation test if not more than 2 of the individual tabletweightsdeviatefromtheaverageweightbymorethantheallowedpercentage deviation and none

deviate by more than twice the % shown. It was calculated on an electronic weighing balance.

#### Friability

The friability values of the tablets were determined using a Roche-friabilator. Accurately weighed six tablets were placed in The Roche friabilator and rotated at 25 RPM for 4 min. Percentage friability was calculated using the following equation. Friability =  $([w_0 - w]/w_0) \times 100$

#### Drug content

The content of drug carried out by 5 randomly selected tablet so each formulation. The 5 tablets were grinded to get powder, this powder was dissolve in pH 6.8 phosphate buffer by sonication for 30min and filtered through filter paper. The drug content was analyzed spectrophotometrically at 294nm using UV spectro photometer. Each measurement was carried out in triplicate and the average drug content was calculated.

#### Disintegration test

Six tablets were taken randomly from each batch and placed in USP disintegration apparatus baskets<sup>(17-23)</sup>. Apparatus was run for 10 min. and the basket was lift from the fluid, observe whether all of the tablets have disintegrated. A piece of tissue paper folded

#### Wetting Time

Piece of tissue paper folded twice was placed in a small petridish containing 6ml of water. A water-soluble dye phenolphthalein was added to the petridish. The dye solution was used to identify the complete wetting of the tablet surface. A tablet was carefully placed on the surface of tissue paper in the petridish at room temperature<sup>16</sup>.

#### Water Absorption Ratio(R)

The weight of the tablet before keeping in the petridish was noted (Wb) using digital balance. The wetted tablet from the petridish was taken and reweighed (Wa-) using the same<sup>(24-27)</sup>. The Water absorption ratio, R, was determined according to the following equation:  $R = (W_a - W_b) / W_b \times 100$

## RESULTS AND DISCUSSION

#### Calibration Curve of Daclatasvir Dihydrochloride

The regression coefficient was found to be 0.999 which indicates linearity with an equation of  $Y = 0.023X - 0.004$ . Hence Beer-Lambert's law was obeyed.




Fig 1: Standard curve of Daclatasvir Dihydrochloride

## Method

In vitro dispersion time was determined by placing one tablet in a beaker containing 10 ml of pH 6.8 phosphate buffer at  $37 \pm 0.5^\circ\text{C}$  and the time required for complete dispersion was determined. To check for reproducibility, the measurements were carried out in triplicates ( $n=3$ ). The dispersion time was recorded using a stopwatch.

## Dissolution test of Daclatasvir Dihydrochloride

Drug release from Daclatasvir Dihydrochloride tablets was determined by using dissolution test USP 24 type II (paddle). The parameters used for performing the dissolution were pH 6.8 medium as the dissolution medium of quantity 900 ml.

## Drug-Excipients compatibility studies


Drug excipients compatibility studies were carried out by mixing the drug with various excipients in different proportions (in 1:1 ratio were to have maximum likelihood interaction between them) was placed in a vial, and closed with rubber stopper and sealed properly. Fourier Transform Infrared Spectroscopy (FTIR) studies were performed on drug, optimized formulation using FTIR. The samples were analyzed between wave numbers  $4000\text{ cm}^{-1}$  and  $550\text{ cm}^{-1}$ .

## Evaluation Of Pre-Compression Parameters of Powder Blend


**Table 1: Evaluation of pre-compression parameters of powder blend**

Formulation Code	Angle of Repose	Bulk Density (gm/mL)	Tapped Density (gm/mL)	Carr's Index (%)	Hausner's Ratio
F1	27.06 $\pm$ 0.02	0.58 $\pm$ 0.06	0.66 $\pm$ 0.07	12.12 $\pm$ 1.13	1.11
F2	27.06 $\pm$ 0.02	0.57 $\pm$ 0.09	0.66 $\pm$ 0.08	13.63 $\pm$ 1.01	1.10
F3	26.57 $\pm$ 0.02	0.56 $\pm$ 0.05	0.65 $\pm$ 0.04	13.84 $\pm$ 0.35	1.08
F4	24.62 $\pm$ 0.03	0.58 $\pm$ 0.05	0.66 $\pm$ 0.07	12.12 $\pm$ 1.27	1.07
F5	24.42 $\pm$ 0.01	0.58 $\pm$ 0.05	0.69 $\pm$ 0.02	13.04 $\pm$ 1.05	1.10
F6	24.42 $\pm$ 0.01	0.61 $\pm$ 0.04	0.69 $\pm$ 0.06	11.59 $\pm$ 1.11	1.10
F7	24.51 $\pm$ 0.02	0.62 $\pm$ 0.04	0.67 $\pm$ 0.04	7.46 $\pm$ 1.36	1.07
F8	24.49 $\pm$ 0.01	0.58 $\pm$ 0.02	0.66 $\pm$ 0.08	12.12 $\pm$ 1.55	1.17
F9	24.45 $\pm$ 0.03	0.58 $\pm$ 0.04	0.66 $\pm$ 0.02	12.12 $\pm$ 0.35	1.08


For each formulation blend of drug and excipients were prepared and evaluated for various recompression parameters described earlier in methodology chapter. The bulk density of all formulations was found in the range of 0.56 $\pm$ 0.05- 0.62 $\pm$ 0.04 and tapped density was in the range of 0.65 $\pm$ 0.04 - 0.69 $\pm$ 0.06. The Carr's index and Hausner's ratio was calculated from tapped density and bulk density.




**Fig 2 : In vitro Disintegration time**



**Fig 3: Wetting time**



**Fig 4: In vitro Dispersion Time**



**Fig 5: Water absorption ratio**


In vitro disintegration studies showed from 19 to 54secs. These results indicate that the F3 formulation which shown less disintegration time than remaining formulations. Wetting time to the time required to wet completely when kept motionless on the tissue paper in a petridish. All the FDT formulations were evaluated for their wetting time as per the procedure described in the methodology section, and the results are shown in table. The average wetting time for all the formulations was in the range of (17to31) seconds.

**In vitro dispersion time**


Daclatasvir Dihydrochloride Mouth Dissolving Tablets F3 formulation dispersed time was 20 secs. It was known that less dispersion time than other formulation. The In vitro dispersion time for all formulation was found to be in a range of 20 to36 seconds. All the formulations were evaluated for water absorption ratio according to the procedure described in methodology section and the results are shown in table. The maximum water absorption ratio was shown by formulation F3 showed 98%. Water absorption ratio is proportional to dissolution rate profile as higher the water absorption ratio Higher the dissolution as shown in the fig 2,3,4 & 5.

**In vitro Dissolution profiles**

The F3 formulation shows 99.42% drug release in 30min while using 45mg concentration of PolyplasdoneXL and disintegration time is 19 sec. In which increase of concentration of PolyplasdoneXL improved dissolution and decreased disintegration so it was optimized formulation. PolyplasdoneXL, Solutab and Explotab are three used as super disintegrants. Finally Concluded that F3 formulation was the optimized Formulation as mentioned in the figure 6 & 7.




**Fig 6: Dissolution profile of formulations F1,F2,F3**




**Fig 7: Dissolution profile of all formulations F1-F9**

## FTIR Results



**Fig 8: FTIR of Daclatasvir Dihydrochloride Pure Drug**



**Fig 9: FTIR of Daclatasvir Dihydrochloride optimized formulation**

Daclatasvir Dihydrochloride was mixed with proportions of excipients showed no color change providing no drug-excipient interactions as represented in the fig 8 & 9.

## CONCLUSION

Conversely in the present investigation, all formulations of the pre and post compression parameters were found to be within limits. The formulation tablets showed compliance for various physicochemical parameters viz. hardness, friability, weight variation, content uniformity and disintegration time. The drug content was within acceptable range which ensured dose uniformity in the formulation. Preformulation studies of Daclatasvir Dihydrochloride were performed; the FT-IR analysis revealed that the super disintegrants and excipients used were compatible with Daclatasvir Dihydrochloride. Mouth dissolving tablets of Daclatasvir Dihydrochloride is to be prepared by direct compression technique using super disintegrants namely PolyplasdoneXL, Solutab and Explotab. Amongst all the formulations, formulation containing PolyplasdoneXL as super disintegrants is for filling all the parameters satisfactorily. It has shown excellent *in vitro* disintegration compared to other super disintegrants. Apart from all the formulations, F3 formulation showed maximum drug release (99.42%) at the end of 30min.

## ACKNOWLEDGEMENT

The Authors wish to express their sincere gratitude to Prathap Narender Reddy College of Pharmacy, Peddeshapur, Shamshad, Telangana, INDIA for providing necessary facilities to carry out this research work & SURAS LAB, Hyderabad, Telangana, INDIA for providing samples for the research work.

## CONFLICT OF INTEREST

We declare that we have no conflict of interest.

## REFERENCES

1. Seager H. Drug delivery products and the zydys fast dissolving dosage form. *J Pharm Pharmacol*. 1998;50(4):375-82. doi: 10.1111/j.2042-7158.1998.tb06876.x, PMID 9625481.
2. Prajapati BG, Patel B. Formulation, evaluation and optimization of orally disintegrating tablet of piroxicam. *Int J Pharm Tech Res*. 2010;2:1893-9.
3. Patidar A, Mishra P, Main P, Harsoliya MS, Agrawal S. A review on recent advancement in the development of rapid disintegrating tablet. *PharmSci Pharm*. 2011;1:7.
4. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery. A review. *Pharm Sci Technol Today*. 2000;3(4):138-45. doi: 10.1016/s1461-5347(00)00247-9, PMID 10754543.
5. Habib W, Khankari RK, Hontz J. Fast-dissolve drug delivery systems. *Crit Rev Ther Drug Carrier Syst*. 2000;17(1):61-72. doi: 10.1615/CritRevTherDrugCarrierSyst.v17.i1.20, PMID 10755211.
6. Lindgren S, Janzon L. Dysphagia: prevalence of swallowing complaints and clinical finding. *Med Clin North Am*. 1993;6:3-5.
7. Muhammad AS, Syed FA, Marium FK, Sofia A, Iqbal A. Formulations of amlodipine: a review. *J Pharmacol*. 2016;1-11. doi: 10.1155/2016/8961621.
8. Deepthi PR, Satish KK. Formulation and evaluation of amlodipine besylate oral thin films. *Int J Pharm Sci Res*. 2016;7:199-205.
9. Shireen B, Syed AAB, Shazia F. Formulation and in-vitro evaluation of mouth dissolving tablets of amlodipine and rosuvastatin. *Int J Curr Pharm Res*. 2015;7:88-91.
10. Nirav VP, Sachin C, Aundhia C, Seth AK. Formulation and evaluation of amlodipine besylate orally disintegrating tablet. *Indo Am J Pharm Res*. 2011;2:146-52.
11. Vijaya VCS, Vidyavathi M. Preparation and in vitro characterization of bosentan monohydrate mucoadhesive microspheres. *Eur J Pharm Res*. 2016;3:340-50.
12. Chatwal GR, Anand SK. Instrumental methods of instrumental methods of chemical analysis. 5th ed. Himalaya Publishing House; 2009. p. 2.49-51.
13. Nirav VP, Sachin C, Aundhia C, Seth AK. Formulation and evaluation of amlodipine besylate orally disintegrating tablet. *Indo Am J Pharm Res*. 2011;2:146-52.
14. Bele MH. *Pharmaceutics formulation and processing of conventional dosage form*. 1st ed. Carrer Publication; 2012. p. 48-55, 128-31.
15. Kalia A, Khurana S, Bedi N. Formulation and evaluation of mouth dissolving tablet of oxcarbazepine. *Int J Pharm Pharm Sci*. 2009;1:12-3.
16. Jain C, Naruka P. Formulation and evaluation of fast dissolving tablet of valsartan. *Int J Pharm Pharm Sci*. 2009;1:219-26.
17. *Indian pharmacopoeia*. Government of India Ministry of Health and Family Welfare. Vol. 2014. Ghaziabad: Indian Pharmacopoeal Commission; 1469, 2143, 2151. p. 2964.
18. Bhardwaj S, Jain V, Jat RC, Mangal A, Jain S. Formulation and evaluation of fast dissolving tablets of aceclofenac. *Int J Drug Deliv*. 2010;2(1):93-7. doi: 10.5138/ijdd.2010.0975.0215.02017.
19. Kuchekar B, Badhan A, Mahajan H. Mouth dissolving tablets of salbutamol sulphate: a novel drug delivery system. *Indian Drugs*. 2004;41:592-8.
20. Arunachalam A, Lavakumar V, Shankar M. Formulation and in vitro evaluation of Levofloxacin Oral dispersible tablets. *Asian J Res Chem PharmSci*. 2013;1:31-9.
21. Dobetti L. Fast melting tablet: development and technologies. *Pharm Technol*. 2001;2:44-8.
22. Lorenzp Lamosa ML, Cuna M, Vila Jato JL, Torres D. Fast dissolving drug delivery system. *J Microencapsul*. 1997;14:607-16.
23. Virley P, Zydis YR. A novel fast dissolving dosage form. *Manuf Chem*. 1990;2:36-7.
24. Shinkar DM, Aher PS, Kothawade PD, Maru AD. Formulation and in vitro evaluation of verapamil hydrochloride. *Int J Pharm Pharm Sci*. 2018;10(10):93-9. doi: 10.22159/ijpps.2018v10i10.28714.
25. Caretensen JT. *Guidelines for drug stability: principles and practices*. 3rd ed. Marcel Dekkar; 2005. p. 252-5.
26. Pratik SD, Sushma V, Puja S. Fast dissolving tablet using solid dispersion technique: a review. *Int J Curr Pharm Res*. 2017;9:1-4.
27. Roy A. Orodispersible tablet: a review. *Asian J Pharm Chem Res*. 2016;2:19-26.